Revium Rx.
Officers & Directors
Amir Avraham, age 49, has served as Interim Chief Executive Officer since May 22, 2025. He was a financial consultant to the company beginning in February 2024. His prior roles include General Manager and Chief Financial Officer at OCON Therapeutics from 2017 to 2024, CFO at Secure Islands Technologies from 2013 to 2017, CFO at Van Leer Technology Ventures from 2008 to 2013, and employment at Deloitte Israel from 2004 to 2008. He is a licensed CPA and holds an MBA in Finance from the Hebrew University of Jerusalem.
Inna Martin, age 49, has been President, Chief Operating Officer, and a Director since December 17, 2024. She joined the company as CEO, President, and Director in November 2019 and served as CEO until December 22, 2024. She has over 20 years of experience in healthcare and project management. Her previous positions include board member of IR Med, Inc. from 2022 to 2024, Investment Director at a Luxembourg healthcare venture capital fund from 2014 to 2018, and founder of Seven Sons Ltd. She holds an MBA from Bar Ilan University, a BA from Orenburg State University, and a certification in AI in Health Care from MIT.
Arie Gordashnikov, age 42, has been Chief Financial Officer since June 1, 2023. He has over 13 years of experience in accounting, auditing, and finance within the high-tech and biotech sectors. Since 2018, he has been Head of the IPO & M&A Department at Shimony Financial Services and was previously an Audit Manager at Ernst & Young Israel from 2009 to 2017. He holds an MBA from Tel Aviv University, a BA from the Hebrew University of Jerusalem, and has been a licensed CPA since 2012.
Bernard Bartal, age 59, has been Chairman, Vice President of Business Development, and a Director since June 2023. He is the founder, co-founder, investor, and strategic contributor to life science and technology ventures, including Dien-A Molecular Biology Ltd. and Advanced Concepts in Biology LLC.
|